Statins in Neuro-ophthalmology

References

• Oesterle KA, Laufs KU, Liao KJ. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120:229–243.
   PubMed Web of Science ®Google Scholar
• Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med. 2005;15:202–206.
   PubMed Web of Science ®Google Scholar
• Campbell WW. Statin myopathy: the iceberg or its tip? Muscle and Nerve. 2006;34:387–390.
   PubMed Web of Science ®Google Scholar
• Nguyen KA, Li L, Lu D, et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol. 2018;74(9):1099–1109.
   PubMed Web of Science ®Google Scholar
• Ooi KG-J, Lee M-HH, Burlutsky G, Gopinath B, Mitchell P, Watson S. Association of dyslipidaemia and oral statin use, and dry eye disease symptoms in the Blue Mountains Eye Study. Clinical & Experimental Ophthalmology. 2018 47(2):187–192.
   Google Scholar
• Ooi KG-J, Lee M-H-H, Burlutsky G, Gopinath B, Mitchell P, Watson S. Association of dyslipidaemia and oral statin use, and dry eye disease symptoms in the blue mountains eye study. Clin Exp Ophthalmol. 2018.
   PubMed Web of Science ®Google Scholar
• Kusner LL, Kaminski HJ. Chapter 10 - myasthenia gravis. In: Zigmond MJ, Rowland LP, Coyle JT, eds. Neurobiology of Brain Disorders. San Diego: Academic Press; 2015:135–150.
   Google Scholar
• Nair A, Patil-Chhablani P, Venkatramani D, Gandhi R. Ocular myasthenia gravis: A review. Indian J Ophthalmol. 2014;62:985–991.
   PubMed Web of Science ®Google Scholar
• Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand. 2014;129:26–31.
   Web of Science ®Google Scholar
• Gras-Champel V, Batteux B, Masmoudi K, Liabeuf S. Statin-induced myasthenia: A disproportionality analysis of the WHO’s VigiBase pharmacovigilance database. Muscle Nerve. 2019;60:382–386.
   PubMed Web of Science ®Google Scholar
• Virgo J, Wong S, Rantell K, Plant G. Statins can cause myasthenia gravis: Fact or fiction? Journal of Neurology, Neurosurgery and Psychiatry Conference: Association of British Neurologists, ABN Joint Meeting with the Royal College of Physicians, RCP. 2013;84(11):90–91.
   Google Scholar
• Elsais A, Lund C, Kerty E. Ptosis, diplopia and statins: an association? Eur J Neurol. 2008;15:e92–93.
   PubMed Web of Science ®Google Scholar
• Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology. 2004;63:2188.
   PubMed Web of Science ®Google Scholar
• Gale J, Danesh-Meyer HV. Statins can induce myasthenia gravis. J Clin Neurosci. 2014;21:195–197.
   PubMed Web of Science ®Google Scholar
• Purvin V, Kawasaki A, Smith KH, Kesler A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine (Baltimore). 2006;85:82–85.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Suzuki S, Nishimura H, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore). 2015;94(4):e416.
   PubMed Web of Science ®Google Scholar
• Keogh MJ, Findlay JM, Leach S, Bowen J. Statin-associated weakness in myasthenia gravis: A case report. J Med Case Rep. 2010;4:61.
   PubMedGoogle Scholar
• Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet. 2002;360:717.
   PubMed Web of Science ®Google Scholar
• Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008;38:1101–1107.
   PubMed Web of Science ®Google Scholar
• Ruiz PJ, Hur EM, Stüve O, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78–84.
   PubMed Web of Science ®Google Scholar
• Conti-Fine BM, Milani M, Wang W. CD4 T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci. 2008;1132:193–209.
   PubMed Web of Science ®Google Scholar
• Negvesky GJ, Kolsky MP, Laureno R, Yau TH. Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia. Arch Ophthalmol. 2000;118:427–428.
   PubMedGoogle Scholar
• Livingstone C, Al Riyami S, Wilkins P, Ferns GAA. McArdle’s disease diagnosed following statin-induced myositis. Ann Clin Biochem. 2004;41:338–340.
   PubMed Web of Science ®Google Scholar
• Baker SK, Tarnopolsky MA. Sporadic rippling muscle disease unmasked by simvastatin. Muscle Nerve. 2006;34:478–481.
   PubMed Web of Science ®Google Scholar
• Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med. 2010;362:564–565.
   PubMed Web of Science ®Google Scholar
• Mahale R, Mehta A, Kempegowda M, et al. Statin-associated ocular myopathy mimicking ocular myasthenia: rare occurrence. (Letter to Editor)(Letter to the editor). Neurol India. 2016;64(4):785.
   PubMed Web of Science ®Google Scholar
• Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol. 2009;22:506–515.
   PubMed Web of Science ®Google Scholar
• Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol. 2010;22:644–650.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Evans MA. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373–418.
   PubMed Web of Science ®Google Scholar
• Mancini GBJ, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a canadian working group consensus conference. Cana J Cardiol. 2011;27(5):635–662.
   PubMed Web of Science ®Google Scholar
• Horvath GHR, Schneiderat EP, Schoser EB, et al. Coenzyme Q10 deficiency and isolated myopathy. Neurology. 2006;66(2):253–255.
   PubMed Web of Science ®Google Scholar
• Toth S, Sajty M, Pekarova T, et al. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. J Basic Clin Physiol Pharmacol. 2017;28(4):327–336.
   PubMedGoogle Scholar
• Tiemstra JD, Khatkhate N. Bell’s palsy: diagnosis and management. Am Fam Physician. 2007;76:997–1002.
   PubMed Web of Science ®Google Scholar
• Schulz JG, Bosel J, Stoeckel M, Megow D, Dirnagl U, Endres M. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem. 2004;89:24–32.
   PubMed Web of Science ®Google Scholar
• Sim FJ, Lang JK, Ali TA, et al. Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation. Glia. 2008;56(9):954–962.
   PubMed Web of Science ®Google Scholar
• Klopfleisch S, Merkler D, Schmitz M, et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci. 2008;28(50):13609–13614.
   PubMed Web of Science ®Google Scholar
• Miron VE, Zehntner SP, Kuhlmann T, et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol. 2009;174(5):1880–1890.
   PubMed Web of Science ®Google Scholar
• Hung SH, Wang LH, Lin HC, Chung SD. Association between statin use and Bell’s palsy: a population-based study. Drug Saf. 2014;1:735–742.
   Web of Science ®Google Scholar
• Chen L, Gordon LK. Ocular manifestations of multiple sclerosis. Current Opinion Ophthalmol. 2005;16:315–320.
   PubMedGoogle Scholar
• Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology. 2002;59(7):990–997.
   PubMed Web of Science ®Google Scholar
• Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363(9421):1607–1608.
   PubMed Web of Science ®Google Scholar
• Tsakiri A, Kallenbach K, Fuglo D, Wanscher B, Larsson H, Frederiksen J. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Multiple Sclerosis. 2012;18:72–81.
   PubMed Web of Science ®Google Scholar
• Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014;383(9936):2213–2221.
   PubMed Web of Science ®Google Scholar
• Eshaghi A, Kievit RA, Prados F, et al. Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. Proc Natl Acad Sci U S A. 2019;116(22):11020–11027.
   PubMed Web of Science ®Google Scholar
• Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol. 2003;60(4):510–515.
   PubMedGoogle Scholar
• Sellner J, Greeve I, Mattle HP. Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. Multiple Sclerosis. 2008;14:981–984.
   PubMed Web of Science ®Google Scholar
• Li XL, Zhang ZC, Zhang B, et al. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse. Int Immunopharmacol. 2014;23(2):546–549.
   PubMed Web of Science ®Google Scholar
• Ghasami K, Faraji F, Fazeli M, Ghazavi A, Mosayebi G. Interferon β-1a and atorvastatin in the treatment of multiple sclerosis. Iran J Immunol. 2016;13:16–26.
   PubMed Web of Science ®Google Scholar
• Togha M, Karvigh SA, Nabavi M, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Multiple Sclerosis. 2010;16(7):848–854.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Pace A, Rani MR. et al., Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology. 2009; 72(23): 1989–1993. test
   PubMed Web of Science ®Google Scholar
• Sorensen P, Lycke J, Erälinna J, et al. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011;10(8):691–701.
   PubMed Web of Science ®Google Scholar
• Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71:1390–1395.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. The history of neuromyelitis optica. Part 2: ‘Spinal amaurosis’, or how it all began. J Neuroinflammation. 2019;16:280.
   PubMed Web of Science ®Google Scholar
• Ratelade J, Verkman AS. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol. 2012;44:1519–1530.
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Duan T, Yeaman MR, Verkman AS. CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation. 2019;16:1.
   PubMed Web of Science ®Google Scholar
• Zhu MX, Lu C, Xia CM, Qiao ZW, Zhu DN. Simvastatin pretreatment protects cerebrum from neuronal injury by decreasing the expressions of phosphor-CaMK II and AQP4 in ischemic stroke rats. J Mol Neurosci. 2014;54:591–601.
   PubMed Web of Science ®Google Scholar
• Kesler A, Goldhammer Y, Gadoth N. Do men with pseudomotor cerebri share the same characteristics as women? A retrospective review of 141 cases. J Neuroophthalmol. 2001;21:15–17.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan K, Ahlskog JE, Garrity JA, Kurland LT. Idiopathic intracranial hypertension. Mayo Clin Proc. 1994;69:169–180.
   PubMed Web of Science ®Google Scholar
• Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53(8):2087.
   PubMed Web of Science ®Google Scholar
• Kesler A, Kliper E, Shenkerman G, Stern N. Idiopathic intracranial hypertension is associated with lower body adiposity. Ophthalmology. 2010;117:169–174.
   PubMed Web of Science ®Google Scholar
• Adderley NJ, Subramanian A, Nirantharakumar K, et al. Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol. 2019;76(9):1088–1098.
   PubMed Web of Science ®Google Scholar
• Hayreh SS. Pathogenesis of optic disc edema in raised intracranial pressure. Prog Retin Eye Res. 2016;50:108–144.
   PubMed Web of Science ®Google Scholar
• Hornby C, Mollan SP, Botfield H, O’Reilly MW, Sinclair AJ. Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. J Neuroophthalmol. 2018;38:522–530.
   PubMed Web of Science ®Google Scholar
• Dodick DW. Migraine. Lancet. 2018;391:1315.
   PubMed Web of Science ®Google Scholar
• Hesami O, Sistanizad M, Asadollahzade E, Johari MS, Beladi-Moghadam N, Mazhabdar-Ghashghai H. Comparing the effects of atorvastatin with sodium valproate (divalproex) on frequency and intensity of frequent migraine headaches: a double-blind randomized controlled study. Clin Neuropharmacol. 2018;41:94–97.
   PubMed Web of Science ®Google Scholar
• Scher IA, Terwindt MG, Picavet SJH, Verschuren MMW, Ferrari DM, Launer JL. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology. 2005;64:614–620.
   PubMed Web of Science ®Google Scholar
• Stang PE, Carson AP, Rose KM, et al. Headache, cerebrovascular symptoms, and stroke: the atherosclerosis risk in communities study. Neurology. 2005;64(9):1573–1577.
   PubMed Web of Science ®Google Scholar
• Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010;123:612–624.
   PubMed Web of Science ®Google Scholar
• Fidan I, Yüksel S, Ýmir T, Irkeç C, Aksakal FN. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J Neuroimmunol. 2006;171:184–188.
   PubMed Web of Science ®Google Scholar
• Perini F, D’ Andrea G, Galloni E, et al. Plasma cytokine levels in migraineurs and controls. Headache. 2005;45(7):926–931.
   PubMed Web of Science ®Google Scholar
• Tietjen GE, Al–Qasmi MM, Athanas K, Dafer RM, Khuder SA. Increased von willebrand factor in migraine. Neurology. 2001;57:334–336.
   PubMed Web of Science ®Google Scholar
• Tietjen EG, Herial AN, White ML, Utley AC, Kosmyna AJ, Khuder AS. Migraine and biomarkers of endothelial activation in young women. Stroke. 2009;40:2977–2982.
   PubMed Web of Science ®Google Scholar
• Davidson HM. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation. 2005;111:2280–2281.
   PubMed Web of Science ®Google Scholar
• Yetkin E, Turhan H. Is it worthwhile to test statin in migraine? Headache. 2007;47:448–450.
   PubMed Web of Science ®Google Scholar
• Medeiros FL, Medeiros PL, Valença MM, Dodick D. Simvastatin for migraine prevention. Headache. 2007;47:855–856.
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Mikhailidis DP. Could statins be useful in the treatment of patients with migraine? Headache. 2006;46:672–675.
   PubMed Web of Science ®Google Scholar
• Yin Z, Fang Y, Ren L, et al. Atorvastatin attenuates NF-kappaB activation in trigeminal nucleus caudalis in a rat model of migraine. Neurosci Lett. 2009;465(1):61–65.
   PubMed Web of Science ®Google Scholar
• Buettner C, Burstein R. Association of statin use and risk for severe headache or migraine by serum vitamin D status: A cross-sectional population-based study. Cephalalgia. 2015;35:757–766.
   PubMed Web of Science ®Google Scholar
• Buettner C, Nir RR, Bertisch SM, et al. Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Ann Neurol. 2015;78(6):970–981.
   PubMed Web of Science ®Google Scholar
• Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Curr Opin Clin Nutr Metab Care. 2005;8:641–646.
   PubMed Web of Science ®Google Scholar
• Qu H, Meng -Y-Y, Chai H, et al. The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials. Eur J Med Res. 2018;23(1):57.
   PubMed Web of Science ®Google Scholar
• Rozen T, Oshinsky M, Gebeline C, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002;22(2):137–141.
   PubMed Web of Science ®Google Scholar
• Sándor SP, Di Clemente ML, Coppola MG, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology. 2005;64(4):713–715.
   PubMed Web of Science ®Google Scholar
• Koster MJ, Warrington KJ, Kermani TA. Update on the epidemiology and treatment of giant cell arteritis. Current Treat Options Rheumatol. 2016;2:138–152.
   Google Scholar
• Almarzouqi SJ, Morgan ML, Lee AG. Treatment of giant cell arteritis. Curr Opin Ophthalmol. 2015;26:469–475.
   PubMed Web of Science ®Google Scholar
• Kay J, Finn DS, Stone JR. Case records of the Massachusetts general hospital. Case 4-2006. A 79-year-old woman with myalgias, fatigue, and shortness of breath. N Engl J Med. 2006;354:623–630.
   PubMedGoogle Scholar
• Garcia-Martinez A, Hernandez-Rodriguez J, Grau JM, Cid MC. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheumatism. 2004;51:674–678.
   PubMed Web of Science ®Google Scholar
• Scolnik M, Mollerach F, Rosa J, Soriano E. Incidence of cardiovascular events in giant cell arteritis: A matched-control study. Rheumatology. 2019;58:2.
   Web of Science ®Google Scholar
• Reiss AB, Glass AD. Atherosclerosis. JInvest Med. 2006;54:123.
   PubMed Web of Science ®Google Scholar
• Hansson GK. Atherosclerosis—An immune disease. Atherosclerosis. 2008;202:2–10.
   PubMed Web of Science ®Google Scholar
• van de Ree MA, Huisman MV, Princen HMG, Meinders AE, Kluft C, Group DA-S. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 2003;166:129–135.
   PubMed Web of Science ®Google Scholar
• Ascer E, Bertolami MC, Venturinelli ML, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis. 2004;177(1):161–166.
   PubMed Web of Science ®Google Scholar
• Fisher MP, Cushman MMDM, Knappertz VMD, Howard GD. An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration. Am Heart J. 2008;156:106–111.
   PubMed Web of Science ®Google Scholar
• Hegg R, Lee AG, Tagg NT, Zimmerman MB. Statin or nonsteroidal anti-inflammatory drug use is associated with lower erythrocyte sedimentation rate in patients with giant cell arteritis. J Neuroophthalmol. 2011;31:135–138.
   PubMed Web of Science ®Google Scholar
• Ly K-H, Régent A, Tamby MC, Mouthon L. Pathogenesis of giant cell arteritis: more than just an inflammatory condition? Autoimmun Rev. 2010;9:635–645.
   PubMed Web of Science ®Google Scholar
• Ma J, Khalidi NA, Wierzbicki O, Al Qethami A, Carette S, Pagnoux C. Impact of diabetes, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis. Arthritis Rheumatol. 2016;68:2680–2681.
   PubMed Web of Science ®Google Scholar
• Narvaez J, Bernad B, Nolla JM, Valverde J. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheumatism. 2007;36:322–327.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Kermani TA, Muratore F, Crowson CS, Matteson EL, Warrington KJ. Statin use in giant cell arteritis: a retrospective study. J Rheumatol. 2013;40:910–915.
   PubMed Web of Science ®Google Scholar
• Ma J, Khalidi NA, Wierzbicki O, Al Qethami A, Carette S, Pagnoux C. Impact of diabetes, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis. Arthritis Rheumatol. 2016;68:2680–2681.
   PubMed Web of Science ®Google Scholar
• Olivas OM, Martin M, Galindo M, Mateo I, Carreira PE. Risk factors associated with cranial ischemic complications in patients with biopsy-proven giant cell arteritis. Ann Rheum Dis. 2015;2:301–302.
   Google Scholar
• De Jong HJI, Meyboom RHB, Helle MJ, Klungel OH, Niskanen L, Tervaert JWC. Giant cell arteritis and polymyalgia rheumatica after reexposure to a statin: A case report. Ann Intern Med. 2014;161:614–615.
   PubMed Web of Science ®Google Scholar
• Pugnet G, Sailler L, Bourrel R, Montastruc JL, Lapeyre-Mestre M. Statins do not influence occurrence or prednisone requirement of giant cell arteritis. A french population-based cohort study. Arthritis Rheumatism. 2013;10:S710.
   Google Scholar
• Hayreh SS. Risk of acute stroke in patients with retinal artery occlusion. Eye. 2019:1–1.
   Google Scholar
• Fallico M, Lotery AJ, Longo A, et al. Risk of acute stroke in patients with retinal artery occlusion: a systematic review and meta-analysis. Eye. 2020;34(4):683–689.
   Google Scholar
• Park SJ, Yang HK, Byun SJ, Park KH, Hwang J-M. Risk of stroke after nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 2019;200:123–129.
   PubMed Web of Science ®Google Scholar
• Chang MY, Keltner JL. Risk factors for fellow eye involvement in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2019;39:147–152.
   PubMed Web of Science ®Google Scholar
• Konstantinos A, Constantina M, Charalambos V, Dimitris T. Statins in Stroke. Curr Med Chem. 2019;26:6174–6185.
   PubMed Web of Science ®Google Scholar
• Lauda F, Neugebauer H, Reiber L, Jüttler E. Acute silent brain infarction in monocular visual loss of ischemic origin. Cerebrovascular Dis. 2015;40:151–156.
   PubMed Web of Science ®Google Scholar
• Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack. Stroke. 2009;40(6):2276–2293.
   PubMed Web of Science ®Google Scholar
• Pula JH, Yuen CA. Eyes and stroke: the visual aspects of cerebrovascular disease. Stroke Vasc Neurol. 2017;2:210–220.
   PubMedGoogle Scholar
• Hoi CP, Chen YT, Fuh JL, Yang CP, Wang SJ. Increased risk of stroke in patients with isolated third, fourth, or sixth cranial nerve palsies: a nationwide cohort study. Cerebrovascular Dis. 2016;41:273–282.
   PubMed Web of Science ®Google Scholar
• Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: A large database analysis of managed care plans in the United States. Clin Ther. 2008;30:195–205.
   PubMed Web of Science ®Google Scholar
• Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904–910.
   PubMed Web of Science ®Google Scholar
• Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18–28.
   PubMed Web of Science ®Google Scholar
• Zhao W, Xiao Z-J, Zhao S-P. The benefits and risks of statin therapy in ischemic stroke: a review of the literature. Neurol India. 2019;67:983–992.
   PubMed Web of Science ®Google Scholar
• Shook SJ, Gupta R, Vora NA, Tievsky AL, Katzan I, Krieger DW. statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke. J Neuroimaging. 2006;16:341–346.
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Saver JL, Starkman S, et al. Statin enhancement of collateralization in acute stroke. Neurology. 2007;68(24):2129.
   PubMed Web of Science ®Google Scholar
• Ford AL, An H, D’Angelo G, et al. Preexisting statin use is associated with greater reperfusion in hyperacute ischemic stroke. Stroke. 2011;42(5):1307–1313.
   PubMed Web of Science ®Google Scholar
• Safouris A, Katsanos AH, Kerasnoudis A, et al. Statin pretreatment and microembolic signals in large artery atherosclerosis. Stroke. 2018;49(8):1992–1995.
   PubMed Web of Science ®Google Scholar
• Tramacere I, Boncoraglio GB, Banzi R, et al. Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Med. 2019;17(1):67.
   PubMed Web of Science ®Google Scholar
• Ricard G, Garant M-P, Carrier N, Leblanc N, Boulanger J-M. Statins may increase intracerebral hemorrhage volume. Can J Neurol Sci/Journal Canadien Des Sciences Neurologiques. 2010;37:791–796.
   PubMed Web of Science ®Google Scholar
• de Lemos J, Braunwald E, Blazing M, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet. 2012;380(9841):581–590.
   Google Scholar
• Oesterle A, Liao JK. The pleiotropic effects of statins - from coronary artery disease and stroke to atrial fibrillation and ventricular tachyarrhythmia. Curr Vasc Pharmacol. 2019;17:222–232.
   PubMed Web of Science ®Google Scholar
• Horodinschi R-N, Stanescu AMA, Bratu OG, Pantea Stoian A, Radavoi DG, Diaconu CC. Treatment with statins in elderly patients. Medicina (Kaunas). 2019;55:721.
   PubMed Web of Science ®Google Scholar
• Barone E, Di Domenico F, Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol. 2014;88:605–616.
   PubMed Web of Science ®Google Scholar
• Tzekov R, Mullan M. Vision function abnormalities in Alzheimer disease. Surv Ophthalmol. 2014;59:414–433.
   PubMed Web of Science ®Google Scholar
• Mendez MF, Tomsak RL, Remler B. Disorders of the visual system in Alzheimer’s disease. J Clin Neuro-ophthalmol. 1990;10:62–69.
   PubMedGoogle Scholar
• Wolin MJ. Alzheimer’s disease and the eye. J S C Med Assoc. 1994;90:534–538.
   PubMedGoogle Scholar
• Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS. Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol. 2015;38:243–250.
   PubMed Web of Science ®Google Scholar
• Fonseca AC, Resende R, Oliveira CR, Pereira CM. Cholesterol and statins in Alzheimer’s disease: current controversies. Exp Neurol. 2010;223:282–293.
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala E-L, Laakso MP, et al. Apolipoprotein E ϵ4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137(3):149–155.
   PubMed Web of Science ®Google Scholar
• Jones RW, Kivipelto M, Feldman H, et al. The atorvastatin/donepezil in alzheimer’s disease study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008;4(2):145–153.
   PubMed Web of Science ®Google Scholar
• Abdullah L, Luis C, Paris D, et al. Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort. Mol Med. 2009;15(11–12):432–437.
   PubMed Web of Science ®Google Scholar
• Donohue MC, Moghadam SH, Roe AD, et al. Longitudinal plasma amyloid beta in Alzheimer’s disease clinical trials. Alzheimers Dement. 2015;11(9):1069–1079.
   PubMed Web of Science ®Google Scholar
• Lashkari K, Teague G, Chen H, et al. A monoclonal antibody targeting amyloid β (Aβ) restores complement factor I bioactivity: potential implications in age-related macular degeneration and Alzheimer’s disease. PLoS One. 2018;13(5). e0195751–e0195751.
   PubMed Web of Science ®Google Scholar
• Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J Neuropsychopharmacol. 2001;4:127–130.
   PubMed Web of Science ®Google Scholar
• Simons M, Schwärzler F, Lütjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52(3):346–350.
   PubMed Web of Science ®Google Scholar
• Carlsson C, Gleason C, Hess T, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer’s disease. J Alzheimer’s Dis. 2008;13(2):187–197.
   PubMed Web of Science ®Google Scholar
• Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol. 2004;61:333–337.
   PubMed Web of Science ®Google Scholar
• Riekse R, Li G, Petrie E, et al. Effect of statins on Alzheimer’s disease biomarkers in cerebrospinal fluid. J Alzheimer’s Dis. 2006;10(4):399–406.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Vega GL, Lutjohann D, et al. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Associated Disord. 2010;24(3):220–226.
   PubMed Web of Science ®Google Scholar
• Yang Y-H, Teng H-W, Lai Y-T, et al. Statins reduces the risk of dementia in patients with late-onset depression: a retrospective cohort study. (Report). PloS One. 2015;10:9.
   Web of Science ®Google Scholar
• Barone E, Di Domenico F, Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol. 2014;88:605–616.
   PubMed Web of Science ®Google Scholar
• Choi S, Jahng WJ, Park SM, Jee D. Association of age-related macular degeneration on alzheimer or parkinson disease: a retrospective cohort study. Am J Ophthalmol. 2020;210:41–47.
   PubMed Web of Science ®Google Scholar
• Sauerbier A, Ray Chaudhuri K. Parkinson’s disease and vision. Basal Ganglia. 2013;3:159–163.
   Google Scholar
• Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in Parkinson’s disease. Vision Res. 2005;45:1285–1296.
   PubMed Web of Science ®Google Scholar
• Kirbas S, Turkyilmaz K, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in parkinson disease. J Neuroophthalmol. 2013;33:62–65.
   PubMed Web of Science ®Google Scholar
• Nowacka B, Lubinski W, Honczarenko K, Potemkowski A, Safranow K. Ophthalmological features of Parkinson disease. Med Sci Monit. 2014;20:2243–2249.
   PubMed Web of Science ®Google Scholar
• Swallow DMA, Lawton MA, Grosset KA, et al. Statins are underused in recent-onset Parkinson’s disease with increased vascular risk: findings from the UK tracking parkinson’s and oxford Parkinson’s disease centre (OPDC) discovery cohorts. J Neurol Neurosurg Psychiatry. 2016;87(11):1183–1190.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yan J, Chen X, et al. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol. 2011;230(1):27–34.
   PubMed Web of Science ®Google Scholar
• Kawada T. Risk reduction of Parkinson disease by statin therapy in patients with diabetes. Ann Neurol. 2017;81:157.
   PubMed Web of Science ®Google Scholar
• Wang Q, Ting WL, Yang H, Wong PT. High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. Br J Pharmacol. 2005;144:933–939.
   PubMed Web of Science ®Google Scholar
• Bai S, Song Y, Huang X, et al. Statin use and the risk of parkinson’s disease: an updated meta-analysis. PloS One. 2016;11(3). e0152564-e0152564.
   Web of Science ®Google Scholar
• Lee Y, Lin C, Wu R, et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology. 2013;81(5):410–416.
   PubMed Web of Science ®Google Scholar
• Mutez E, Duhamel A, Defebvre L, Bordet R, Destée A, Kreisler A. Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson’s disease. Pharmacol Res. 2009;60:41–45.
   PubMed Web of Science ®Google Scholar
• Jeong SM, Jang W, Shin DW. Association of statin use with Parkinson’s disease: dose-response relationship. Movement Disorders. 2019;34:1014–1021.
   PubMed Web of Science ®Google Scholar
• Ooi KGJ, Wakefield D, Billson FA, Watson SL. Efficacy and safety of topical atorvastatin for the treatment of dry eye associated with blepharitis: a pilot study. Ophthalmic Res. 2015;54:26–33.
   PubMed Web of Science ®Google Scholar
• Kostis JB, Dobrzynski JM. Prevention of cataracts by statins: a meta-analysis. J Cardiovasc Pharmacol Ther. 2014;19:191–200.
   PubMed Web of Science ®Google Scholar
• Kostis JB, Dobrzynski JM. Prevention of cataract by statins. Am J Cardiol. 2016;117:1196.
   PubMed Web of Science ®Google Scholar